RxDoctor Payments Data

Thomas Scholler, PA

Physician Assistant · Tyler, TXNPI 1467444141

Payments from drug & device makers

$1,800in general payments, 2019–2025

Across 82 payments — averaging $21.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$312
  • Pfizer$299
  • Sanofi-aventis U.S. LLC$249
  • E.r. Squibb & Sons, L.L.C.$149
  • Abbott$141
  • Johnson & Johnson$136
  • plus $515 from 7 others

What the payments were for

  • Food & beverage$1,800100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,800 in reported general payments places this provider in the 75th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$90,957
Medicare patients
890
Services billed
1,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,304$1,062,269
XareltoRivaroxaban413$362,566
MultaqDronedarone Hcl156$184,391
Metoprolol Succinate665$11,394
Flecainide Acetate287$9,535
Amiodarone Hcl341$9,488
Dofetilide49$5,126
SotalolSotalol Hcl293$4,878
Digoxin129$3,072
Dabigatran EtexilateDabigatran Etexilate Mesylate13$2,592
Metoprolol Tartrate239$1,977
Carvedilol154$1,903
Diltiazem 12hr ErDiltiazem Hcl11$1,615
Diltiazem 24hr Er (Cd)Diltiazem Hcl53$1,149
Propafenone Hcl12$1,047

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$299$1,062,2691,304 claims
Johnson & JohnsonXarelto$136$362,566413 claims
Sanofi-aventis U.S. LLCMultaq$249$184,391156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →